Printer Friendly

Oscient Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Discuss FACTIVE(R) sNDA for Acute Bacterial Sinusitis.

WALTHAM, Mass. -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced that NASDAQ has halted trading of Oscient common stock.

The Anti-Infective Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to review and discuss the Company's supplemental New Drug Application (sNDA) for FACTIVE(R) (gemifloxacin mesylate) tablets seeking approval as treatment for acute bacterial sinusitis (ABS).

About Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to the clinical development and commercialization of novel therapeutics to address unmet medical needs. The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity and ANTARA(R) 130 mg (fenofibrate) capsules, FDA-approved for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. Oscient has a novel antibiotic candidate, Ramoplanin, in advanced clinical development for the treatment of Clostridium difficile-associated disease (CDAD).

Forward-Looking Statement

This news release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements related to the review by the Anti-Infective Drugs Advisory Committee to the FDA regarding the sNDA for FACTIVE seeking approval as treatment for ABS. Forward-looking statements represent our management's judgment regarding future events. Forward-looking statements typically are identified by use of terms such as "may," "will," "should," "plan," "expect," "intend," "anticipate," "estimate," and similar words, although some forward-looking statements are expressed differently. We do not plan to update these forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements due to a number of risks affecting our business. For example, our ability to increase our revenue and accelerate the time of our profitability may be limited by: (i) our ability to successfully commercialize and market FACTIVE or ANTARA due to: the limitations on our resources and experience in the commercialization of products; lack of acceptance by physicians, patients and third party payors; unanticipated safety, product liability, efficacy, or other regulatory issues; delays in recruiting and training sales personnel; problems relating to manufacturing or supply; inadequate distribution of the products by wholesalers, pharmacies, hospitals and other customers; and competition from other products; (ii) our ability to integrate ANTARA into our business; (iii) whether we will be able to expand the indications for which FACTIVE is approved; (iv) the delay or inability to find sublicensing partners for FACTIVE or to negotiate favorable licensing terms; (v) the delay in or inability to obtain additional regulatory approvals of our products and product candidates due to negative, inconclusive or insufficient results in ongoing or future clinical trials, the FDA requiring additional information or data, delays in the progress of ongoing clinical trials, safety concerns arising with respect to our products or product candidates and disputes with the third parties from whom we license our products or product candidate; and (vi) delays by the FDA. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2006 and in other filings that we may make with the Securities and Exchange Commission from time to time.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 12, 2006
Words:555
Previous Article:iLoop Mobile Acquires InAphone Denmark to Grow Mobile Text and Content Business Worldwide; iLoop Mobile Expands Services Capability and Application...
Next Article:Conexant's Dual-RF Tuner Wins ``Best Silicon Innovation'' in Annual ``Cable and Satellite'' Award Competition; Consecutive Wins Highlight Conexant's...
Topics:


Related Articles
Telithromycin for the treatment of acute bacterial maxillary sinusitis: a review of a new antibacterial agent.
Cubist Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss CUBICIN(R) sNDA.
Oscient Pharmaceuticals Announces Meeting Date for FDA Advisory Committee to Address sNDA for Five-Day Treatment of Acute Bacterial Sinusitis with...
Oscient Pharmaceuticals and Auxilium Pharmaceuticals Agree to Conclude TESTIM(R) Co-Promotion Partnership.
Oscient Pharmaceuticals Announces Results of FDA Advisory Committee Meeting for FACTIVE Tablets for the Treatment of Acute Bacterial Sinusitis.
Oscient Pharmaceuticals Provides Preliminary Revenue Results for Third Quarter 2006.
Oscient Pharmaceuticals Reports Financial Results for Third Quarter of 2006.
Oscient Pharmaceuticals and Pfizer, S.A. de C.V. Announce Launch of FACTIVE(R) Tablets in Mexico.
Reverse Split of Oscient Pharmaceuticals Stock to Be Effected with Market Open November 16, 2006.
FDA Approves Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters